MindMed (MMED) is trading 13% up at $15.53 in pre-market, driven by positive developments in its clinical pipeline. - The company, formerly known as Definium, announced on June 22, 2026, that its LSD-based therapy, DT120, achieved "profound" efficacy in a Phase 3 trial for major depressive disorder. - Analysts from Stifel and Jefferies noted that the results exceeded expectations and could support a fundamentally new approach to treating MDD.